These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

424 related articles for article (PubMed ID: 31582354)

  • 41. Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy.
    Thompson PA; Srivastava J; Peterson C; Strati P; Jorgensen JL; Hether T; Keating MJ; O'Brien SM; Ferrajoli A; Burger JA; Estrov Z; Jain N; Wierda WG
    Blood; 2019 Nov; 134(22):1951-1959. PubMed ID: 31537528
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial.
    Hillmen P; Pitchford A; Bloor A; Broom A; Young M; Kennedy B; Walewska R; Furtado M; Preston G; Neilson JR; Pemberton N; Sidra G; Morley N; Cwynarski K; Schuh A; Forconi F; Elmusharaf N; Paneesha S; Fox CP; Howard DR; Hockaday A; Brown JM; Cairns DA; Jackson S; Greatorex N; Webster N; Shingles J; Dalal S; Patten PEM; Allsup D; Rawstron A; Munir T
    Lancet Oncol; 2023 May; 24(5):535-552. PubMed ID: 37142374
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The outcome of chronic lymphocytic leukemia patients who relapsed after fludarabine, cyclophosphamide, and rituximab.
    Panovská A; Smolej L; Lysák D; Brychtová Y; Šimkovič M; Motyčková M; Vodárek P; Lindtnerová M; Trbušek M; Malčíková J; Pospíšilová Š; Mayer J; Doubek M
    Eur J Haematol; 2013 Jun; 90(6):479-85. PubMed ID: 23506191
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Progress in the treatment of chronic lymphocytic leukemia: results of the German CLL8 trial.
    Molica S
    Expert Rev Anticancer Ther; 2011 Sep; 11(9):1333-40. PubMed ID: 21929307
    [TBL] [Abstract][Full Text] [Related]  

  • 45. FCR front-line therapy and quality of life in patients with chronic lymphocytic leukemia.
    Kutsch N; Busch R; Bahlo J; Mayer J; Hensel M; Hopfinger G; Hess G; von Grünhagen U; Wendtner CM; Maria Fink A; Fischer K; Hallek M; Eichhorst B
    Leuk Lymphoma; 2017 Feb; 58(2):399-407. PubMed ID: 27357445
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Integrative prognostic models predict long-term survival after immunochemotherapy in chronic lymphocytic leukemia patients.
    Bloehdorn J; Krzykalla J; Holzmann K; Gerhardinger A; Jebaraj BMC; Bahlo J; Humphrey K; Tausch E; Robrecht S; Mertens D; Schneider C; Fischer K; Hallek M; Döhner H; Benner A; Stilgenbauer S
    Haematologica; 2022 Mar; 107(3):615-624. PubMed ID: 33730841
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations.
    Jain N; Thompson P; Burger J; Ferrajoli A; Takahashi K; Estrov Z; Borthakur G; Bose P; Kadia T; Pemmaraju N; Sasaki K; Konopleva M; Jabbour E; Garg N; Wang X; Kanagal-Shamanna R; Patel K; Wang W; Jorgensen J; Wang S; Lopez W; Ayala A; Plunkett W; Gandhi V; Kantarjian H; O'Brien S; Keating M; Wierda WG
    Leukemia; 2021 Dec; 35(12):3421-3429. PubMed ID: 34007049
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia.
    Byrd JC; Kipps TJ; Flinn IW; Castro J; Lin TS; Wierda W; Heerema N; Woodworth J; Hughes S; Tangri S; Harris S; Wynne D; Molina A; Leigh B; O'Brien S
    Blood; 2010 Jan; 115(3):489-95. PubMed ID: 19843887
    [TBL] [Abstract][Full Text] [Related]  

  • 49. FCR and bevacizumab treatment in patients with relapsed chronic lymphocytic leukemia.
    Jain P; Lee HJ; Qiao W; Wierda W; Benjamini O; Burger J; Ferrajoli A; Estrov Z; Kantarjian H; Keating M; O'Brien S
    Cancer; 2014 Nov; 120(22):3494-501. PubMed ID: 25043749
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Clinical efficacy and safety of chemoimmunotherapy with rituximab,fludarabine and cyclophosphamide for chronic lymphocytic leukemia].
    Li F; Yi SH; Yu Z; Xing LJ; Xu Y; Qi JY; Zhao YZ; Li ZJ; Qiu LG
    Zhonghua Xue Ye Xue Za Zhi; 2013 May; 34(5):383-8. PubMed ID: 23688746
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukaemia patients: Final analysis of the Phase IIIb GREEN study.
    Stilgenbauer S; Bosch F; Ilhan O; Kisro J; Mahé B; Mikuskova E; Osmanov D; Reda G; Robinson S; Tausch E; Turgut M; Wójtowicz M; Böttcher S; Perretti T; Trask P; Van Hoef M; Leblond V; Foà R
    Br J Haematol; 2021 Apr; 193(2):325-338. PubMed ID: 33605445
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Point: Does Chemoimmunotherapy Still Have a Role in CLL? Chemoimmunotherapy With FCR Is Still an Important Option in CLL.
    Thompson PA; Tam CS
    Oncology (Williston Park); 2018 Jun; 32(6):291-2, 294-6. PubMed ID: 29940059
    [No Abstract]   [Full Text] [Related]  

  • 53. Comparison between oral and intravenous fludarabine plus cyclophosphamide regime as front-line therapy in patients affected by chronic lymphocytic leukaemia: influence of biological parameters on the clinical outcome.
    Laurenti L; De Padua L; Tarnani M; Piccirillo N; Falcucci P; D'Arena G; Innocenti I; Marietti S; Efremov DG; Chiusolo P; Zini G; Sora' F; Sica S; Leone G
    Ann Hematol; 2011 Jan; 90(1):59-65. PubMed ID: 20625902
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Sustained remissions in CLL after frontline FCR treatment with very-long-term follow-up.
    Thompson PA; Bazinet A; Wierda WG; Tam CS; O'Brien SM; Saha S; Peterson CB; Plunkett W; Keating MJ
    Blood; 2023 Nov; 142(21):1784-1788. PubMed ID: 37595283
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy.
    Byrd JC; Gribben JG; Peterson BL; Grever MR; Lozanski G; Lucas DM; Lampson B; Larson RA; Caligiuri MA; Heerema NA
    J Clin Oncol; 2006 Jan; 24(3):437-43. PubMed ID: 16344317
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia.
    Parikh SA; Keating MJ; O'Brien S; Wang X; Ferrajoli A; Faderl S; Burger J; Koller C; Estrov Z; Badoux X; Lerner S; Wierda WG
    Blood; 2011 Aug; 118(8):2062-8. PubMed ID: 21750315
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacokinetics and safety of subcutaneous rituximab plus fludarabine and cyclophosphamide for patients with chronic lymphocytic leukaemia.
    Assouline S; Buccheri V; Delmer A; Gaidano G; McIntyre C; Brewster M; Catalani O; Hourcade-Potelleret F; Sayyed P; Badoux X
    Br J Clin Pharmacol; 2015 Nov; 80(5):1001-9. PubMed ID: 25900065
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial.
    Herling CD; Cymbalista F; Groß-Ophoff-Müller C; Bahlo J; Robrecht S; Langerbeins P; Fink AM; Al-Sawaf O; Busch R; Porcher R; Cazin B; Dreyfus B; Ibach S; Leprêtre S; Fischer K; Kaiser F; Eichhorst B; Wentner CM; Hoechstetter MA; Döhner H; Leblond V; Kneba M; Letestu R; Böttcher S; Stilgenbauer S; Hallek M; Levy V
    Leukemia; 2020 Aug; 34(8):2038-2050. PubMed ID: 32071431
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Fludarabine-Cyclophosphamide-Rituximab Treatment in Chronic Lymphocytic Leukemia, Focusing on Long Term Cytopenias Before and After the Era of Targeted Therapies.
    Szász R; Telek B; Illés Á
    Pathol Oncol Res; 2021; 27():1609742. PubMed ID: 34257611
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Reduced-dose fludarabine, cyclophosphamide, and rituximab (FCR-Lite) plus lenalidomide, followed by lenalidomide consolidation/maintenance, in previously untreated chronic lymphocytic leukemia.
    Mato AR; Foon KA; Feldman T; Schuster SJ; Svoboda J; Chow KF; Valentinetti M; Mrkulic M; Azzollini K; Gadaleta G; Bhattacharyya PK; Zenreich J; Pascual LN; Yannotti K; Kdiry S; Howlett C; Strelec L; Porter D; Bejot C; Goy A
    Am J Hematol; 2015 Jun; 90(6):487-92. PubMed ID: 25691474
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.